• SAR131675: Precision VEGFR-3 Inhibitor for Fibrosis and Angi

  2026-07-24

  SAR131675 offers unmatched selectivity as a VEGFR-3 inhibitor, enabling researchers to dissect lymphangiogenesis, angiogenesis, and macrophage-driven fibrosis pathways with high experimental fidelity. Unique protocol parameters and troubleshooting insights make it the anti-lymphangiogenic agent of choice for advanced vascular and hepatic fibrosis models.

• Tropisetron Hydrochloride: Applied Workflows & 5-HT3 Antagon

  2026-07-23

  Tropisetron Hydrochloride stands out as a dual-action 5-HT3 receptor antagonist and α7-nicotinic receptor agonist, enabling precision targeting in neuroscience and transporter interaction studies. APExBIO’s high-purity reagent empowers robust protocols for serotonin receptor signaling and renal OCT2/MATE1 inhibition, supporting advanced pharmacological and translational research.

• AP20187: Precision Chemical Inducer of Dimerization in Gene

  2026-07-23

  AP20187 is a synthetic, cell-permeable chemical inducer of dimerization enabling precise control of protein-protein interactions in conditional gene expression systems. This article details its mechanism, quantitative performance benchmarks, and key applications in regulated cell therapy and metabolic research.

• WAY-100635 in Translational Neuropharmacology: Beyond Antago

  2026-07-22

  Explore the multifaceted applications of WAY-100635 in advanced neuroscience and pain research. This article provides an in-depth look at its mechanism, practical assay strategies, and emerging insights that set it apart from standard serotonin receptor antagonists.

• Sodium Disrupts Mitochondria to Drive NECSO: Mechanistic Ins

  2026-07-22

  Qiao et al. reveal that excessive sodium influx impairs mitochondrial energy metabolism, triggering necrotic cell death by suppressing oxidative phosphorylation and the TCA cycle. This mechanistic link between sodium overload and mitochondrial dysfunction advances our understanding of necrosis and highlights methodological parallels with classic mitochondrial ATP synthase inhibition.

• Clozapine N-oxide (CNO): Reliable Chemogenetic Tool for Neur

  2026-07-21

  This article presents scenario-driven, evidence-based guidance for leveraging Clozapine N-oxide (CNO, SKU A3317) in advanced chemogenetic and cell-viability assays. By addressing real-world laboratory challenges—from optimizing DREADDs activation to data interpretation and vendor selection—we highlight how CNO’s high purity and validated performance (as supplied by APExBIO) support reproducibility and innovation in neuroscience research.

• Indazole/Indole Glucagon Receptor Antagonists: Synthesis and

  2026-07-21

  This study presents the development of a novel series of indazole- and indole-based glucagon receptor antagonists, structurally inspired by MK 0893. The research demonstrates potent in vitro and in vivo inhibition of glucagon-induced glucose excursion, offering promising leads for type 2 diabetes research and preclinical evaluation.

• Amitriptyline HCl: Technical Guidance for Neuropharmacology

  2026-07-20

  Amitriptyline HCl (SKU B2231) addresses the need for a well-characterized, high-purity tricyclic compound in studies of neurotransmitter receptor modulation, especially in neuropharmacology and mood disorder models. This article provides actionable, protocol-level guidance for its use and highlights critical storage, solubility, and workflow considerations. Researchers should avoid speculative applications outside the documented receptor modulation and neuropsychiatric disorder research scope.

• Miltefosine: Redefining Leukopenia Research via Dual Pathway

  2026-07-20

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) transforms leukopenia and hematology research with dual modulation of the PI3K/Akt and Ras/MEK/ERK pathways. This guide translates the latest breakthroughs into actionable protocols, troubleshooting guidance, and comparative insights for advanced experimental design.

• Deep Learning Predicts Cardiotoxicity in iPSC-CM Screening

  2026-07-19

  Grafton et al. introduce a deep learning-driven platform to rapidly detect drug-induced cardiotoxicity using high-content imaging in iPSC-derived cardiomyocytes. This approach enables scalable early-stage screening for cardiac safety, addressing a major bottleneck in drug development.

• Update on Palonosetron Hydrochloride for CINV/RINV Preventio

  2026-07-18

  This article reviews the innovation and clinical significance of palonosetron hydrochloride as detailed in Fabi & Malaguti’s systematic literature update. The reference study highlights palonosetron’s unique pharmacological properties and its superior efficacy in preventing delayed chemotherapy- and radiotherapy-induced nausea and vomiting, with practical implications for cancer research and clinical antiemetic protocols.

• Targeted Amikacin Delivery to Granulomas via Dendritic Cells

  2026-07-17

  Montes-Worboys et al. demonstrate a novel approach for delivering Amikacin directly into Mycobacterium avium granulomas using monocyte-derived dendritic cells as carriers. This targeted delivery method achieves high local antibiotic concentrations while minimizing systemic toxicity, offering new insights into managing non-tuberculous mycobacterial infections.

• Metronidazole for Research Use: OAT3 Inhibition & Workflow A

  2026-07-17

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) stands out as a dual-purpose tool—precise OAT3 inhibitor and nitroimidazole antibiotic—enabling advanced workflows in drug transporter, microbiome, and anaerobic bacteria research. This guide details protocol parameters, troubleshooting, and strategic experimental designs for translational scientists seeking robust, reproducible results.

• Cimetidine as a Histamine-2 Receptor Antagonist in BBB Model

  2026-07-16

  Cimetidine’s distinct partial agonist activity at the H2 receptor makes it a precision tool for dissecting histamine-2 signaling in advanced in vitro blood-brain barrier (BBB) models. This article delivers actionable workflow guidance for maximizing reproducibility—highlighting practical troubleshooting, protocol parameters, and the translational impact of APExBIO’s high-purity Cimetidine in CNS and gastrointestinal cancer research.

• Pharmacological SMYD2 Inhibition Attenuates Cisplatin-Induce

  2026-07-16

  This study demonstrates that pharmacological inhibition of SMYD2, particularly using AZ505, mitigates cisplatin-induced renal fibrosis and inflammation in chronic kidney disease models. The findings highlight SMYD2 as a key epigenetic regulator in renal pathology, providing a mechanistic foundation for targeted intervention strategies.

7891 records 5/527 page Previous Next 12345 下5页 Last page